--- title: Will the FDA’s Response To Curaleaf Set the Standard for On-Line CBD Sales? description: The Food and Drug Administration issued a warning letter to Curaleaf, Inc. to stop selling CBD products that are unapproved and misbranded drugs within 15 days. The FDA reviewed Curaleaf’s social media accounts during April and June 2019, and determined that the products were “intended for use in the diagnosis, cure, mitigation, treatment, or prevention […] image: https://cdn.prod.website-files.com/66525ec138843cc1ccb1c325/68c301ebaa36be33aa2af8f7_1a3f16114a452999cc4d7d6b36ae1602_Obedio%20march%20of%20progress.png --- [Skip to content](https://hs.getobedio.com/blog/2019/07/30/2019-7-30-will-the-fdas-response-to-curaleaf-set-the-standard-for-on-line-cbd-sales#main-content) [![Obedio logo with black text and an orange graphic composed of four circles and a diagonal arrow pointing up and right.](https://cdn.prod.website-files.com/66525ec138843cc1ccb1c325/66529844eddaa630d6da1b42_obedio%20gold%20for%20white%20background.png)](https://getobedio.com) [Team](https://www.getobedio.com/team) [Pricing](https://www.getobedio.com/pricing) [Contact](https://www.getobedio.com/demo) [Blog](https://www.getobedio.com/blog) [Login](https://obed.io/v4/login) CBD Oil # Will the FDA’s Response To Curaleaf Set the Standard for On-Line CBD Sales? ![Susan Ameel](https://7528315.fs1.hubspotusercontent-na1.net/hub/7528315/hubfs/raw_assets/public/mV0_d-cms-elevate-theme_hubspot/elevate/images/avatar-placeholder.jpg?width=48&height=48&name=avatar-placeholder.jpg) Susan Ameel July 30, 2019 The Food and Drug Administration issued a [warning letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curaleaf-inc-579289-07222019) to Curaleaf, Inc. to stop selling CBD products that are unapproved and misbranded drugs within 15 days. The FDA reviewed Curaleaf’s social media accounts during April and June 2019, and determined that the products were “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.” Curaleaf sold the CBD products, including a lotion, pain-relief patch, tincture and disposable vape pen on its own [website](https://curaleafhemp.com/) as well as[Twitter](https://twitter.com/curaleafhemp) and [Facebook](https://www.facebook.com/CuraleafHemp), which the FDA considered to be interstate commerce. Curaleaf updated its Facebook cover photo a day after receiving the letter to remove products that included words on the label that reflect an effect on the body such as [relieve, revive, and uplift](https://www.facebook.com/CuraleafHemp/photos/a.223611381783904/323236371821404/?type=3&theater). However, these photos are still available in the archives and in the Facebook feed. Curaleaf, Inc. is a public company that is listed on the Canadian Stock Exchange and can be purchased by US investors on the OTC market. In its [response](https://ir.curaleaf.com/press-releases/detail/72/curaleaf-sends-response-to-fda-letter) to the FDA on July 26, Curaleaf indicated that the company was in the process of reviewing its social media sites and that the company discontinued the products in question. Curaleaf’s stock has rebounded after initially falling to close at $7.40 on July 23, 2019. The FDA is clearly making a statement by issuing a warning letter to such a large industry player. The question is whether the FDA will be satisfied with the steps Curaleaf has taken. This is a big risk with significant ramifications for the company. The FDA’s stance will set the standard in the CBD industry for what will be considered acceptable online marketing standards. The industry will be holding its breath. ## Share this post [mailto:https%3A%2F%2Fhs.getobedio.com%2Fblog%2F2019%2F07%2F30%2F2019-7-30-will-the-fdas-response-to-curaleaf-set-the-standard-for-on-line-cbd-sales](mailto:https%3A%2F%2Fhs.getobedio.com%2Fblog%2F2019%2F07%2F30%2F2019-7-30-will-the-fdas-response-to-curaleaf-set-the-standard-for-on-line-cbd-sales) ## Keep reading ### [California Ballot Measure Local Municipalities California voters will decide 118 local tax measures and $8.07 billion in bond requests on November 3](https://hs.getobedio.com/blog/california-voters-will-decide-118-local-tax-measures-and-8.07-billion-in-bond-requests-on-november-3) ### [Local Ordinance Zoning Ordinance Development Data Federal Realty Asks La Mesa to Approve a 165,000-Square-Foot Bass Pro Shops Where Macy's Stood at Grossmont Center](https://hs.getobedio.com/blog/federal-realty-asks-la-mesa-to-approve-a-165000-square-foot-bass-pro-shops-where-macys-stood-at-grossmont-center) [![Obedio your municipal data source](https://hs.getobedio.com/hs-fs/hubfs/google%20workspace-1.png?width=100&height=41&name=google%20workspace-1.png "Obedio your municipal data source")](https://getobedio.com) Obedio's business intelligence platform provides data and insights from over 25,000 municipalities, enabling retail, manufacturing, finance, real estate, and government clients to make informed decisions, assess risk, and identify opportunities. **Data Source & Liability Disclaimer:** The data presented on this website is aggregated from various official government and public entities ("The Original Government Sources"). This data may have been modified for use from its original source. The Original Government Sources do not vouch for the quality, accuracy, or timeliness of the data as presented here. All data is provided "as is." Neither Global Regulatory Risk Advisors, Inc. (d/b/a Obedio) nor The Original Government Sources make any representations or warranties as to the completeness, accuracy, or content of any data made available through this site. All warranties, whether express or implied, including implied warranties of merchantability or fitness for a particular purpose, are expressly disclaimed. **Usage & Intellectual Property:** While the underlying facts are public records, the specific compilation, organization, and presentation of this information are proprietary to ****Global Regulatory Risk Advisors, Inc. (d/b/a Obedio)****. Any unauthorized copying, distribution, or display of this proprietary presentation is prohibited. Copyright © 2018–2026 Global Regulatory Risk Advisors, Inc. (d/b/a Obedio) [|](https://getobedio.com/privacy)[Terms of Service](https://getobedio.com/terms)[|](https://getobedio.com/privacy)[Privacy Policy](https://getobedio.com/privacy) Privacy Policy · Legal · © 2025. All rights reserved. ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Susan Ameel", "url" : "https://hs.getobedio.com/blog/author/susan-ameel" }, "dateModified" : "2025-02-28T01:24:31.504Z", "datePublished" : "2019-07-30T13:32:08.000Z", "headline" : "Will the FDA’s Response To Curaleaf Set the Standard for On-Line CBD Sales?", "mainEntityOfPage" : { "@id" : "https://hs.getobedio.com/blog/2019/07/30/2019-7-30-will-the-fdas-response-to-curaleaf-set-the-standard-for-on-line-cbd-sales", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://hs.getobedio.com/hubfs/google%20workspace-1.png" } } } ``` ```json { "@context" : "https://schema.org", "@id" : "https://hs.getobedio.com/blog/2019/07/30/2019-7-30-will-the-fdas-response-to-curaleaf-set-the-standard-for-on-line-cbd-sales#breadcrumb", "@type" : "BreadcrumbList", "itemListElement" : [ { "@type" : "ListItem", "item" : "https://www.getobedio.com/", "name" : "Home", "position" : 1 }, { "@type" : "ListItem", "item" : "https://hs.getobedio.com/blog", "name" : "Blog", "position" : 2 }, { "@type" : "ListItem", "item" : "https://hs.getobedio.com/blog/2019/07/30/2019-7-30-will-the-fdas-response-to-curaleaf-set-the-standard-for-on-line-cbd-sales", "name" : "Will the FDA’s Response To Curaleaf Set the Standard for On-Line CBD Sales?", "position" : 3 } ] } ```